US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.44

-0.0900-1.99%

Post-market: 4.37-0.0700-1.58%19:57 EDT

Volume:770.90K

Turnover:3.37M

Market Cap:462.05M

PE:-1.17

High:4.66

Open:4.53

Low:4.28

Close:4.53

52wk High:13.11

52wk Low:2.76

Shares:104.06M

Float Shares:80.76M

Volume Ratio:0.79

T/O Rate:0.95%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.8055

EPS(LYR):-10.3816

ROE:-66.35%

ROA:-59.84%

PB:0.95

PE(LYR):-0.43

Loading ...

Overview Company News Filings

Alumis Price Target Announced at $18.00/Share by Guggenheim

Alumis Inc. Files Initial Statement of Beneficial Ownership for Director Lynn A. Tetrault

Alumis, Acelyrin Close Merger

MT Newswires Live

Alumis Inc. Completes Merger with ACELYRIN, Strengthening Late-Stage Biopharma Portfolio

Alumis Inc. Conducted Virtual Special Stockholder Meeting

Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating

MT Newswires Live

Alumis Q1 Sales $17.39M

Alumis Inc. Stockholders Approve Merger with ACELYRIN, Anticipating Successful Close in Q2 2025

Press Release: Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires Live

Alumis, Acelyrin Shareholders Approve Merger Deal

MT Newswires Live

BRIEF-Alumis Stockholders Approve Merger With Acelyrin

Acelyrin Stockholders Approve Merger with Alumis to Form Biopharma Company Focused on Immune-mediated Diseases

Foresite Labs Reports Acquisition of Common Shares of Alumis Inc

Acelyrin Inc. Urges Stockholders to Vote for Value-Maximizing Merger with Alumis Ahead of Special Meeting

Press Release: ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Alumis Price Target Maintained With a $14.00/Share by HC Wainwright & Co.

BRIEF-Alumis And Acelyrin Announce Amended Merger Agreement

Alumis Raises Share Consideration for Acelyrin Acquisition

MT Newswires Live

Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":4.44,"timestamp":1760126400000,"preClose":4.53,"halted":0,"volume":770895,"hourTrading":{"tag":"盘后","latestPrice":4.37,"preClose":4.44,"latestTime":"19:57 EDT","volume":10592,"amount":46975.1008,"timestamp":1760140669035},"delay":0,"floatShares":80756771,"shares":104064302,"eps":-3.805488,"marketStatus":"Closed","change":-0.09,"latestTime":"10-10 16:00:00 EDT","open":4.53,"high":4.66,"low":4.275,"amount":3372435.5128424997,"amplitude":0.084989,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.805488,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760342400000},"marketStatusCode":5,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":4.53,"preHourTrading":{"tag":"盘前","latestPrice":4.6,"preClose":4.53,"latestTime":"09:24 EDT","volume":27,"amount":123.609996,"timestamp":1760102687227},"postHourTrading":{"tag":"盘后","latestPrice":4.37,"preClose":4.44,"latestTime":"19:57 EDT","volume":10592,"amount":46975.1008,"timestamp":1760140669035},"volumeRatio":0.789751,"impliedVol":0.5157,"impliedVolPercentile":0.0156},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":80756771,"roa":"-59.84%","roe":"-66.35%","lyrEps":-10.381567,"volumeRatio":0.789751,"shares":104064302,"dividePrice":0,"high":4.66,"amplitude":0.084989,"preClose":4.53,"low":4.275,"week52Low":2.7601,"pbRate":"0.95","psRate":"23.04","week52High":13.11,"institutionHeld":0,"latestPrice":4.44,"eps":-3.805488,"divideRate":0,"volume":770895,"delay":0,"ttmEps":-3.805488,"open":4.53,"prevYearClose":7.86,"prevWeekClose":4.02,"prevMonthClose":3.99,"prevQuarterClose":3.99,"fiveDayClose":4.02,"twentyDayClose":4.37,"sixtyDayClose":3.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17},{"market":"US","date":"2025-05-14","symbol":"ALMS","fiscalQuarterEnding":"2025/03","expectedEps":-1.47,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.82},{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1753502400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-10-09","current":-1.166736,"percent":0.383901,"low":-4.913756,"twenty":-3.392543,"median":-1.867544,"eighty":-0.80289,"high":-0.443678,"avg":-1.993174,"sd":1.163681,"marketCap":461004857},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-09","current":-2.026235,"twenty":-3.392543,"median":-1.867544,"eighty":-0.80289,"marketCap":461004857}],"updateTime":1760151671305},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542830345","title":"Alumis Price Target Announced at $18.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2542830345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542830345?lang=en_us&edition=fundamental","pubTime":"2025-06-10 23:02","pubTimestamp":1749567720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2025 11:02 ET (15:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2537154103","title":"Alumis Inc. Files Initial Statement of Beneficial Ownership for Director Lynn A. Tetrault","url":"https://stock-news.laohu8.com/highlight/detail?id=2537154103","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537154103?lang=en_us&edition=fundamental","pubTime":"2025-05-24 04:03","pubTimestamp":1748030639,"startTime":"0","endTime":"0","summary":"Alumis Inc. has filed an initial statement of beneficial ownership. The filing names Lynn A. Tetrault as the beneficial owner, who serves as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL58LCY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2537939084","title":"Alumis, Acelyrin Close Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2537939084","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537939084?lang=en_us&edition=fundamental","pubTime":"2025-05-21 22:14","pubTimestamp":1747836871,"startTime":"0","endTime":"0","summary":"Alumis  said Wednesday that it has completed its merger with Acelyrin .Each Acelyrin shareholder will receive 0.4814 Alumis share for each Acelyrin share owned. Acelyrin shares have ceased trading on Nasdaq.\"This merger allows us to advance our pipeline through multiple planned key data readouts, with a cash runway that now extends into 2027,\" Alumis Chairman, CEO and President Martin Babler, said.Alumis shares were up over 8% in recent trading.Price: 5.28, Change: +0.40, Percent Change: +8.20","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","ALMS","SLRN"],"gpt_icon":0},{"id":"2537359599","title":"Alumis Inc. Completes Merger with ACELYRIN, Strengthening Late-Stage Biopharma Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2537359599","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537359599?lang=en_us&edition=fundamental","pubTime":"2025-05-21 21:16","pubTimestamp":1747833390,"startTime":"0","endTime":"0","summary":"Alumis Inc., a late-stage biopharma company specializing in next-generation targeted therapies for immune-mediated diseases, has successfully completed its merger with ACELYRIN, Inc. This strategic move establishes a leading clinical-stage biopharma company with a robust portfolio and a strong financial position. As part of the merger, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share they own. With this merger, Alumis aims to advance its pipeline and extend its cash runway into 2027, ensuring continued development of transformative therapies for patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL1Tk9ws:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALMS","BK4007","SLRN"],"gpt_icon":0},{"id":"2536637627","title":"Alumis Inc. Conducted Virtual Special Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2536637627","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536637627?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:06","pubTimestamp":1747685167,"startTime":"0","endTime":"0","summary":"Alumis Inc. held a virtual special meeting of its stockholders on May 13, 2025. During the meeting, stockholders voted on two key proposals. The proposal to approve the issuance of shares of Common Stock to stockholders of ACELYRIN in connection with the merger was approved. Additionally, the proposal to approve the adjournment from time to time of the Special Meeting, if necessary, to solicit additional proxies was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDLbbNDpx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2535540847","title":"Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2535540847","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535540847?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:23","pubTimestamp":1747311827,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of buy and mean price target of $21.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","ALMS"],"gpt_icon":0},{"id":"2535585000","title":"Alumis Q1 Sales $17.39M","url":"https://stock-news.laohu8.com/highlight/detail?id=2535585000","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535585000?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:29","pubTimestamp":1747254561,"startTime":"0","endTime":"0","summary":"Alumis (NASDAQ:ALMS) reported $17.39 million in sales this quarter.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421234/alumis-q1-sales-17-39m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2535072450","title":"Alumis Inc. Stockholders Approve Merger with ACELYRIN, Anticipating Successful Close in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2535072450","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535072450?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:22","pubTimestamp":1747254138,"startTime":"0","endTime":"0","summary":"Alumis Inc., a clinical-stage biopharmaceutical company, announced an update on its merger agreement with ACELYRIN, Inc. On May 13, 2025, Alumis stockholders approved all proposals related to the pending merger during a Special Meeting of Stockholders. The merger, slated for completion in the second quarter of 2025, aims to enhance value creation opportunities for both companies' stockholders. The amended agreement stipulates that ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock per ACELYRIN share. Post-merger, Alumis stockholders will hold approximately 52% of the combined entity, while ACELYRIN stockholders will own around 48% on a fully diluted basis. The merger is expected to advance a differentiated clinical pipeline and provide financial flexibility for strategic opportunities in immune-mediated diseases.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL277fdN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2535020710","title":"Press Release: Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2535020710","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535020710?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:05","pubTimestamp":1747253100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May 14, 2025  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones.Babler continued, \"We are also focused on the anticipated close of the merger with ACELYRIN in the second quarter of this year. We continue to believe that the merger will support the advancement of a differentiated clinical pipeline combined with enhanced financial flexibility to enable strategic opportunities across a broad range of immune-mediated diseases, creating value for patients and stockholders.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2028103732.USD","BK4007","LU1162221912.USD","LU0098860793.USD","LU2111349929.HKD","LU0006306889.USD","LU2089283258.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU2347655156.SGD","LU1720051017.SGD","LU2357305700.SGD","LU2089284900.SGD","ALMS","BK4127","LU0314104364.USD","LU1548497426.USD","LU2133065610.SGD","LU0158827948.USD","LU2023251221.USD","BK4588","BK4516","LU0795875086.SGD","LU0106831901.USD","LU1732800096.USD","LU0106261372.USD","LU0912757837.SGD","LU1720051108.HKD","LU2271345857.HKD","LU0971096721.USD","LU0320765646.SGD","LU1074936037.SGD","LU1989772840.SGD","LU1989772923.USD","BK4585","LU0225283273.USD","LU1363072403.SGD","LU1732799900.SGD","LU0267386448.USD","BK4534","LU0795875169.SGD","BK4581","LU1668664300.SGD","LU0158827781.USD","BK4504"],"gpt_icon":0},{"id":"2535882090","title":"Sector Update: Health Care Stocks Decline Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2535882090","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535882090?lang=en_us&edition=fundamental","pubTime":"2025-05-14 02:05","pubTimestamp":1747159552,"startTime":"0","endTime":"0","summary":"Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index falling 2.6% and the Health Care Select Sector SPDR Fund  dropping 2.3%.The iShares Biotechnology ETF  shed 1.5%.In corporate news, UnitedHealth  suspended its full-year outlook amid higher-than-expected medical costs, while Andrew Witty stepped down as chief executive due to \"personal reasons.\" UnitedHealth shares fell more than 16%.Alumis  shares fell past 8%. Shareholders of Alumis andAcelyrin  separately approved their merger deal at  special meetings. Acelyrin shares also fell over 9%.CNS Pharmaceuticals  shares jumped 35% after the company said it has acquired from Cortice Biosciences an orphan drug designation for late-stage abeotaxane TPI 287 as a potential treatment for glioblastoma multiforme.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1037948541.HKD","BK4533","IE0004445239.USD","LU0029864427.USD","LU0211328371.USD","LU0289739699.SGD","IE00BWXC8680.SGD","LU2028103732.USD","LU0058720904.USD","LU2279689827.SGD","LU0738911758.USD","LU0708995401.HKD","LU1003077747.HKD","LU0251132253.USD","IE00B1XK9C88.USD","LU1069347547.HKD","IE00BJT1NW94.SGD","IE00B4JS1V06.HKD","LU0689472784.USD","CNSP","LU1854103824.USD","BK4534","XLV","BK4154","LU0097036916.USD","LU0079474960.USD","LU0528227936.USD","IE00B19Z9Z06.USD","LU1778281490.HKD","LU2491050071.SGD","UNH","LU0320765059.SGD","LU1914381329.SGD","LU1670628061.USD","IBB","LU1153585028.USD","IE00BZ1G4Q59.USD","LU0456855351.SGD","LU1261432733.SGD","IE00BKVL7J92.USD","LU0109391861.USD","BK4581","ALMS","IE00B775H168.HKD","LU0820561909.HKD","IE00BFSS8Q28.SGD","IE00B19Z3B42.SGD","SLRN","LU0234572021.USD","LU1720051108.HKD"],"gpt_icon":1},{"id":"2535970033","title":"Alumis, Acelyrin Shareholders Approve Merger Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2535970033","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535970033?lang=en_us&edition=fundamental","pubTime":"2025-05-14 01:22","pubTimestamp":1747156969,"startTime":"0","endTime":"0","summary":"Alumis  said Tuesday its shareholders approved its pending merger with Acelyrin  at a special shareholder meeting.Separately, Acelyrin also said its stockholders approved its merger agreement with Alumis at a special meeting. Acelyrin stockholders will receive 0.4814 shares of Alumis stock for each Acelyrin share.They expect to close the merger in the second quarter.Price: 4.83, Change: -0.42, Percent Change: -8.00","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4139","SLRN","BK4007"],"gpt_icon":0},{"id":"2535707818","title":"BRIEF-Alumis Stockholders Approve Merger With Acelyrin","url":"https://stock-news.laohu8.com/highlight/detail?id=2535707818","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535707818?lang=en_us&edition=fundamental","pubTime":"2025-05-14 01:05","pubTimestamp":1747155924,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Stockholders Approve Merger With AcelyrinMay 13 (Reuters) - Alumis Inc ALMS.O:ALUMIS STOCKHOLDERS APPROVE MERGER WITH ACELYRINALUMIS INC - MERGER EXPECTED TO CLOSE IN Q2 2025Source text: ID:nGNXbDPfFWFurther company coverage: ALMS.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nTUA8N9TNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007","SLRN","BK4139"],"gpt_icon":0},{"id":"2535702774","title":"Acelyrin Stockholders Approve Merger with Alumis to Form Biopharma Company Focused on Immune-mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2535702774","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535702774?lang=en_us&edition=fundamental","pubTime":"2025-05-14 01:00","pubTimestamp":1747155612,"startTime":"0","endTime":"0","summary":"LOS ANGELES, May 13, 2025  -- ACELYRIN, Inc. , a late-stage clinical biopharma company, announced that its stockholders have approved the merger with Alumis Inc. . At a special meeting held today, ACELYRIN stockholders voted in favor of the merger agreement, which stipulates that they will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. The merger aims to create a biopharma company dedicated to developing and commercializing transformative therapies for immune-mediated diseases. The transaction is expected to be completed in the second quarter of 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acelyrin Inc. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDLvGnWr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","LU2210149790.SGD","LU2210150020.SGD","BK4585","BK4007","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4588","ALMS","BK4139"],"gpt_icon":0},{"id":"2533102617","title":"Foresite Labs Reports Acquisition of Common Shares of Alumis Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2533102617","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533102617?lang=en_us&edition=fundamental","pubTime":"2025-05-07 09:56","pubTimestamp":1746583001,"startTime":"0","endTime":"0","summary":"Foresite Labs, LLC, along with Foresite Labs Affiliates 2021, LLC, reported an acquisition of common shares of Alumis Inc. The filing indicates that these entities are among the beneficial owners, with other reporting beneficial owners also involved. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL1jMxGb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2532327886","title":"Acelyrin Inc. Urges Stockholders to Vote for Value-Maximizing Merger with Alumis Ahead of Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2532327886","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532327886?lang=en_us&edition=fundamental","pubTime":"2025-05-02 01:30","pubTimestamp":1746120616,"startTime":"0","endTime":"0","summary":"ACELYRIN, Inc. has announced its confidence in a proposed merger with Alumis Inc., scheduled for a stockholder vote on May 13, 2025. The merger aims to create a leading clinical-stage immunology company with a diversified portfolio of product candidates. ACELYRIN's Board of Directors emphasizes that the merger represents the culmination of a comprehensive and competitive process designed to maximize value for all stockholders. ACELYRIN stockholders are expected to retain approximately 48% ownership in the combined company, providing them with significant potential upside. The Board encourages stockholders to focus on the long-term benefits of the merger.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acelyrin Inc. published the origina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL7fZyRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B3QW5Z07.USD","BK4007","IE00BGHQF748.EUR","SLRN","LU2095319765.USD","BK4588","NDAQ","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BKPKM429.USD","BK4112","ALMS"],"gpt_icon":0},{"id":"2532859188","title":"Press Release: ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis","url":"https://stock-news.laohu8.com/highlight/detail?id=2532859188","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532859188?lang=en_us&edition=fundamental","pubTime":"2025-05-02 01:30","pubTimestamp":1746120600,"startTime":"0","endTime":"0","summary":"Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025. Reminds stockholders to vote today FOR the proposed merger. LOS ANGELES, May 01, 2025  -- ACELYRIN, Inc. , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc.  is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders.Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee , said, \"The ACELYRIN Board and management team are confident that the proposed merger with Alumis represents the most value-maximizing path forward for our company's stockholders. The agreement with Alumis follows a comprehensive and competitive process facilitated by the ACELYRIN Board. Furthermore, it reflects successful efforts by our Board to negotiate a revised agreement with a mea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","SLRN","BK4007","BK4139"],"gpt_icon":0},{"id":"2531870530","title":"Alumis Price Target Maintained With a $14.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2531870530","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531870530?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:46","pubTimestamp":1746009960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 06:46 ET (10:46 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2529870756","title":"BRIEF-Alumis And Acelyrin Announce Amended Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2529870756","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529870756?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:53","pubTimestamp":1745236410,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis And Acelyrin Announce Amended Merger AgreementApril 21 (Reuters) - Alumis Inc ALMS.O:ALUMIS AND ACELYRIN ANNOUNCE AMENDED MERGER AGREEMENTALUMIS INC - ACELYRIN STOCKHOLDERS TO RECEIVE 0.4","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA46YLXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","BK4007","ALMS"],"gpt_icon":0},{"id":"2529141872","title":"Alumis Raises Share Consideration for Acelyrin Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2529141872","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529141872?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:17","pubTimestamp":1745234276,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) and Acelyrin (SLRN) said Monday that they agreed on an amended merger deal that reflects an increased share consideration for each Acelyrin share.Under the amended agreement, Acelyrin sh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLRN","BK4139","ALMS","BK4007"],"gpt_icon":0},{"id":"2529879600","title":"Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879600","media":"Dow Jones","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529879600?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:30","pubTimestamp":1745231400,"startTime":"0","endTime":"0","summary":"ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis. Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the Board Transaction Committee, said, \"Since announcing the merger, we have had extensive conversations with our stockholders who have expressed an understanding of the strategic rationale for this transaction, while also sharing their perspectives on the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}]}}